2025-06-13-Jefferies-光束治疗公司（BEAM）_镰状细胞更新情况良好；为2026年下半年提交申请做准备_8页_471kb

Beam Therapeutics Equity Research Summary

Flash Note

• H2:26 Filing Potential; Updated Phase I/II sickle cell data from EHA shows strong efficacy with mean HbF induction >60% in 17 patients vs. VRTX Casgevy at ~45%. Data from ASH demonstrates higher efficacy. No vaso-occlusive crises; safety profile consistent with prior updates. Pivotal enrollment expected mid-2025, potentially leading to FDA filing by YE 2026.

Sickle Cell Disease Update

• Updated Phase I/II data shows durable HbF levels (>60%) maintained up to 15 months; no patients experienced crises. Engraftment rapid (17 days for neutrophils, 20 days for platelets). Treatment is "safer and easier" with even HbF distribution, reducing sickling risk and improving hemolysis biomarkers.
• Comparison to competitors: Higher HbF levels than Casgevy, faster engraftment, better safety. Vertex's Casgevy has achieved $14M sales in Q1:25.
• Key improvements: Normalization of hemolysis markers, reduced inflammatory biomarkers, indicating better red blood cell health.

Pivotal Development and Filing

• Pivotal cohort (n=30) enrollment expected mid-2025, setting up potential FDA filing by YE 2026. Company treated 26 patients; Phase I/II study fully completed across adult and adolescent cohorts.
• Commercial opportunity: Growing demand for sickle cell disease treatments (supply lagging demand); Medicaid reimbursement model covers 84% of patients, improving market access.

Market Opportunity and Competition

• Sickle cell market maturing; demand outpaces supply, reimbursement improving. Beam's data positions it as a leader with superior efficacy and safety. Competitive threats include Vertex (VRTX); however, Beam's updated AATD and engineering programs offer differentiation.
• Analysts note Beam's platform works but face challenges in SMID biotech environment.

Valuation and Investment Outlook

• Jefferies HOLD rating; price target $20.00 (15% upside from current $17.44); 52-week high-low $35.25-$13.53. Market cap $2.0B.
• Risks: Competition, efficacy/safety data limitations, biotech market challenges. Jefferies assesses NPV of probability-adjusted indications; SOTP supports $300/sh for CF base, with pipeline value.
• Key catalysts: Updated AATD data in H2:25, pivotal study completion, FDA filing.

Other Programs and Catalysts

• AATD gene editing: Dosing higher (75 mg cohort); plans to enroll patients with liver involvement starting H2. Expected H2:25 data update.
• ESCAPE program: Phase I study for "chemo-free" treatment aiming to accelerate engraftment.
• Additional catalysts: Continued market expansion, reimbursement improvements, partnerships (e.g., Jefferies underwriting role).

Analyst Notes

• Michael J. Yee et al. certify views reflect personal opinions; disclosures include analyst equity positions (e.g., Dina Elmonshed and Madeleine Lee at Vertex). Jefferies provided investment banking services to Beam. Rating update history tracks price targets and holds.